Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes
Metrics: PDF 1637 views | HTML 1833 views | ?
Melissa M. Norström1,*, Emelie Rådestad2,*, Berit Sundberg2, Jonas Mattsson2,3, Lars Henningsohn4, Victor Levitsky5,8, Michael Uhlin2,3,6,7
1Pharmaceutical Sciences (PS), Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland
2Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
3Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital, Huddinge, Sweden
4Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm, Sweden
5Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Zurich, Switzerland
6Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden
7Department of Applied Physics, Royal Institute of Technology, Stockholm, Sweden
8Current address: Oncology Research, Molecular Partners AG, Zurich, Switzerland
*These authors have contributed equally to this work
Emelie Rådestad, e-mail: email@example.com
Keywords: benign prostatic hyperplasia, prostate-infiltrating lymphocytes, immunophenotyping, cytokine/chemokine profiling, inflammation
Received: December 03, 2015 Accepted: February 28, 2016 Published: March 14, 2016
Benign prostatic hyperplasia (BPH) is a common chronic non-malignant condition whose prevalence substantially increases with age. Immune cell infiltration and pro-inflammatory mediators have been implicated in the pathogenesis. Here, we characterized 21 extracellular markers on prostate-infiltrating lymphocytes (PILs) and analyzed expression of 26 soluble proteins in prostate tissue obtained from BPH patients (n = 31). These data were correlated with clinical parameters and compared with peripheral blood mononuclear cells (PBMCs) (n = 10). Increased frequencies of T cells expressing co-inhibitory receptors LAG-3, PD-1, TIM-3 or CTLA-4, and co-stimulatory receptors CD28, OX40 or 4-1BB were observed in BPH tissue compared to PBMCs. These findings are consistent with chronic activation and possible functional exhaustion of PILs that may be further augmented by several identified pro-inflammatory factors, such as IL-8 and MCP-1, promoting inflammation and chemotaxis of immune cells to the prostate. Prostate size and plasma prostate-specific antigen levels positively correlated with IL-8 and MCP-1 concentrations, and frequencies of T cells expressing CTLA-4 and TIM-3. It remains to be established whether the link between inflammation and BPH progression supported by our findings reflects a progressive failure of the immune system leading to decreased immune surveillance and development of prostate cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.